Registered number
15939167
HQ Pharma LTD
Filleted Abridged Accounts
30 September 2025

HQ Pharma LTD
Registered number: | 15939167
Abridged Balance Sheet
as at 30 September 2025
Notes |  |  | 2025 |
£ |
Fixed assets
Tangible assets | 3 |  |  | 7,556
Current assets
Cash at bank and in hand |  |  | 3,886
Creditors: amounts falling due within one year |  |  | (1,787)
Net current assets |  |  |  | 2,099 |
Net assets |  |  |  | 9,655 |
Capital and reserves
Called up share capital |  |  |  | 1
Profit and loss account |  |  |  | 9,654
Shareholder's funds |  |  |  | 9,655 |
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A) of the Companies Act 2006.
Humaira Qadeer
Director
Approved by the board on 3 June 2026

HQ Pharma LTD
Notes to the Abridged Accounts
for the period from 5 September 2024 to 30 September 2025
1 | Accounting policies
| Basis of preparation
| The abridged accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
| Turnover
| Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
| Tangible fixed assets
| Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
| Freehold buildings | over 50 years
| Leasehold land and buildings | over the lease term
| Plant and machinery | over 5 years
| Motor Vehicles | over 4 years fixed
| Debtors
| Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
| Creditors
| Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
| Taxation
| A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
| Provisions
| Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2 | Employees | 2025 |
Number |
| Average number of persons employed by the company | 1
3 | Tangible fixed assets
|  |  |  |  |  |  |  | Total
£
| Cost
| Additions | 8,243
| At 30 September 2025 | 8,243
| Depreciation
| Charge for the period | 687
| At 30 September 2025 | 687
| Net book value
| At 30 September 2025 | 7,556
4 | Other information
| HQ Pharma LTD is a private company limited by shares and incorporated in England. Its registered office is:
| 47 Burton Road
| Branston
| Burton On Trent
| Staffordshire
| DE14 3DL

HQ Pharma LTD 15939167 false 2024-09-05 2025-09-30 2025-09-30 VT Final Accounts February 2026 Humaira Qadeer No description of principal activity 15939167 2024-09-05 2025-09-30 15939167 bus:PrivateLimitedCompanyLtd 2024-09-05 2025-09-30 15939167 bus:AuditExemptWithAccountantsReport 2024-09-05 2025-09-30 15939167 bus:Director40 2024-09-05 2025-09-30 15939167 1 2024-09-05 2025-09-30 15939167 2 2024-09-05 2025-09-30 15939167 countries:England 2024-09-05 2025-09-30 15939167 bus:FRS102 2024-09-05 2025-09-30 15939167 bus:AbridgedAccounts 2024-09-05 2025-09-30 15939167 2025-09-30 15939167 core:WithinOneYear 2025-09-30 15939167 core:ShareCapital 2025-09-30 15939167 core:RetainedEarningsAccumulatedLosses 2025-09-30 15939167 2024-09-04 iso4217:GBP xbrli:pure